Pyxis Oncology (NASDAQ:PYXS) Upgraded to “Strong-Buy” at Wells Fargo & Company

Wells Fargo & Company upgraded shares of Pyxis Oncology (NASDAQ:PYXS) to a strong-buy rating in a research report report published on Monday, MarketBeat Ratings reports. Wells Fargo & Company currently has $12.00 price objective on the stock.

Several other brokerages have also recently commented on PYXS. Weiss Ratings cut Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. Wall Street Zen lowered shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Leerink Partners dropped their price objective on shares of Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating for the company in a research note on Thursday, July 2nd. Finally, Wedbush assumed coverage on shares of Pyxis Oncology in a report on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Pyxis Oncology presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.50.

Pyxis Oncology Stock Up 14.7%

Pyxis Oncology stock opened at $3.04 on Monday. The business has a 50 day moving average price of $2.28 and a two-hundred day moving average price of $1.88. The stock has a market cap of $192.58 million, a price-to-earnings ratio of -2.32 and a beta of 1.31. Pyxis Oncology has a 12 month low of $0.97 and a 12 month high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). On average, analysts expect that Pyxis Oncology will post -1.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pyxis Oncology

Hedge funds and other institutional investors have recently modified their holdings of the stock. Atle Fund Management AB acquired a new position in Pyxis Oncology during the fourth quarter worth $710,000. 683 Capital Management LLC lifted its holdings in shares of Pyxis Oncology by 69.9% during the fourth quarter. 683 Capital Management LLC now owns 891,910 shares of the company’s stock valued at $1,026,000 after acquiring an additional 366,910 shares during the period. OMERS ADMINISTRATION Corp acquired a new stake in shares of Pyxis Oncology in the 4th quarter valued at $77,000. Barclays PLC grew its holdings in shares of Pyxis Oncology by 1,939.3% in the 4th quarter. Barclays PLC now owns 60,385 shares of the company’s stock worth $69,000 after purchasing an additional 57,424 shares during the last quarter. Finally, HRT Financial LP grew its holdings in shares of Pyxis Oncology by 157.5% in the 4th quarter. HRT Financial LP now owns 39,649 shares of the company’s stock worth $45,000 after purchasing an additional 24,251 shares during the last quarter. Institutional investors own 39.07% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.